Pharmacovigilance

Pharmacovigilance
Name	Pharmacovigilance
Purpose	Monitoring safety of medicinal products
Established	1960s
Key organizations	World Health Organization, European Medicines Agency, U.S. Food and Drug Administration

Pharmacovigilance is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug‑related problems. It encompasses spontaneous reporting systems, post‑marketing surveillance, pharmacoepidemiology, and signal management to protect public health and inform regulatory action. Practitioners collaborate across academia, industry, and public institutions to interpret safety data, guide clinical practice, and update product information.

History

Early roots trace to events such as the Thalidomide tragedy and the subsequent legislative and institutional responses including the formation of the U.S. Food and Drug Administration's strengthened drug safety roles and the expansion of pharmacovigilance in the European Union. The post‑1960s era saw creation of national centers like the Yellow Card Scheme in the United Kingdom and global coordination under the World Health Organization's Programme for International Drug Monitoring. Landmark documents and directives, including regulatory frameworks from the Council of Europe and directives promulgated by the European Medicines Agency, codified adverse event reporting and risk minimization. Key figures and institutions including regulatory chairs, academic pioneers at institutions such as Harvard Medical School, Johns Hopkins University, and industry pharmacovigilance leaders shaped methods and policy debates at forums like the World Health Assembly.

Definitions and Scope

The scope comprises post‑authorization safety studies, clinical trial safety monitoring, medication error surveillance, and vaccine safety oversight as performed by authorities like the U.S. Food and Drug Administration, the European Medicines Agency, and the Paul Ehrlich Institute. Definitions intersect with disciplines such as pharmacoepidemiology practiced at places like the London School of Hygiene & Tropical Medicine and biostatistics groups at the National Institutes of Health. Terminology standards are maintained by organizations including the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and coding dictionaries produced by the WHO Collaborating Centre for Drug Statistics Methodology. Professional societies such as the International Society of Pharmacovigilance and academic journals from publishers like Elsevier provide guidance on case causality, benefit–risk assessment, and lifecycle safety management.

Methods and Data Sources

Surveillance methods range from spontaneous reports submitted to databases like the WHO Global Individual Case Safety Reports (VigiBase) and the FDA Adverse Event Reporting System to active surveillance using electronic health records from systems such as the Clinical Practice Research Datalink and claims databases maintained by organizations like Centers for Medicare & Medicaid Services. Analytical techniques include disproportionality analysis developed in pharmacovigilance groups at the Uppsala Monitoring Centre, propensity score methods taught at Columbia University, and sequential analysis used by vaccine safety teams at the Centers for Disease Control and Prevention. Data sources extend to literature indexed in PubMed, registries operated by institutions such as the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance, and patient‑reported outcomes collected via initiatives led by World Health Organization partners and nonprofit groups including the Wellcome Trust.

Regulatory Framework and International Organizations

Regulation is enacted through statutory agencies like the U.S. Food and Drug Administration, the European Medicines Agency, and the Pharmaceuticals and Medical Devices Agency in Japan, with harmonization efforts coordinated by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and guidance from the World Health Organization. International collaborations include the Uppsala Monitoring Centre hosting the WHO database and interagency work with the Centers for Disease Control and Prevention for vaccine safety, while regional mechanisms involve governance by the African Union’s health bodies and networks coordinated through the Pan American Health Organization. Legal instruments and pharmacovigilance commitments are embedded within directives from bodies such as the Council of the European Union and legislative frameworks like acts administered by the U.S. Congress.

Signal Detection and Risk Management

Signal detection employs statistical disproportionality methods pioneered within the Uppsala Monitoring Centre and sequential monitoring frameworks used by teams at the Centers for Disease Control and Prevention and the Food and Drug Administration. Case assessment integrates causality algorithms influenced by work at The Cochrane Collaboration and expert committees convened by the European Medicines Agency and national pharmacovigilance centers. Risk management includes risk evaluation and mitigation strategies (REMS) overseen by the U.S. Food and Drug Administration, risk management plans (RMPs) mandated by the European Medicines Agency, and post‑authorization safety studies contracted with academic sites like Oxford University and Imperial College London. Communication of safety signals occurs via drug safety communications from agencies such as the Food and Drug Administration and European public assessment reports issued by the European Medicines Agency.

Challenges and Ethical Considerations

Challenges include underreporting documented in studies from institutions like Johns Hopkins University and data quality variability across systems such as national electronic health records in France and Germany. Ethical considerations arise concerning informed consent in post‑marketing studies reviewed by institutional review boards at universities like Stanford University and the balance between transparency promoted by entities such as Transparency International and proprietary data held by pharmaceutical companies like Pfizer and GlaxoSmithKline. Equity issues surface in global access to safety surveillance capacity, addressed by capacity building from the World Health Organization and funding agencies such as the Bill & Melinda Gates Foundation. Emerging topics include pharmacovigilance for personalized therapies developed at centers like Memorial Sloan Kettering Cancer Center and real‑world evidence initiatives led by consortia including the Observational Health Data Sciences and Informatics network.

Category:Medicine